BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Shares of Aclaris Therapeutics ACRS rallied 53.2% on Monday and gained another 8.9% during the after-market hours following ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

Shares of Aclaris Therapeutics (NASDAQ:ACRS) soared 60% Tuesday, the day after the company announced it was licensing two ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...

Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announced that it has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights ...